2008 Trends to Watch: Pharmaceutical Technology

Table of Contents

• DATAMONITOR VIEW
  • CATALYST
  • SUMMARY
• ANALYSIS
  • The industry is plagued by generic competition due to blockbuster drugs coming off patent
    • The golden age of Big Pharma and blockbuster drugs is over
  • Mounting drug safety concerns puts pressure on regulatory bodies, especially the FDA
    • Pharmaceutical companies accuse the FDA of being overly-cautious
  • Pharmaceutical companies are restructuring their business models to adapt to the changing environment
    • The pharmaceutical industry turns to biotechnology for the next blockbuster
• ACTIONS
  • Impact on the life science industry
    • It is essential for the life science industry to streamline operations
    • The pharmaceutical industry must embrace IT to shift away from the "blockbuster drug" business model
    • New regulations will require companies to have better data management
  • Recommendations for technology vendors
    • Vendors need to demonstrate that IT solutions will optimize business processes
    • IT vendors must prove their products will aid global market development
    • Customer focus is essential to penetrate the market
• APPENDIX
  • Definitions
  • Methodology
  • Further reading
  • Ask the analyst
  • Datamonitor consulting
  • Disclaimer
  • List of Figures
    • Figure 1: Drug discovery & development process
    • Figure 2: Number of branded drugs going off patent between 2008-2012
    • Figure 3: Number of new molecular entities (NMEs) and biologics approved by the FDA, 1980-2007
    • Figure 4: Number of layoffs announced by Big Pharma in 2006-2007